Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …

Globally, breast cancer is the most common cancer type and is one of the most significant
causes of deaths in women. To date, multiple clinical interventions have been applied …

Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field
of cancer therapy. However, similar to other chemotherapeutic agents such as cisplatin …

Doxorubicin (Dox)‐mediated generation of reactive oxygen radicals (ROS) for mitochondrial
apoptosis is identified as a new cytotoxic mechanism in addition to the well‐established one …

Simple Summary Breast cancer (BC) is the most common cancer diagnosed among women
worldwide. Despite numerous studies, the pathogenesis of BC is still poorly understood, and …

Drug resistance is a major problem in cancer treatment, as it limits the effectiveness of
pharmacological agents and can lead to disease progression. Cold atmospheric plasma …

Nanomedicine is a field that combines biology and engineering to improve disease
treatment, particularly in cancer therapy. One of the promising techniques utilized in this …

Cancer treatment faces many hurdles and resistance is one among them. Anti-cancer
treatment strategies are evolving due to innate and acquired resistance capacity, governed …

Chemotherapy agents often exhibit limited effectiveness due to their fast elimination from the
body and non-targeted delivery. Emerging nanomaterials as drug delivery carriers open …

Simple Summary The effectiveness and safety of the anti-cancer agent doxorubicin
(anthracycline group medicine) depend on the metabolism and retention of the drug in the …